集成与分离方式在需连续性肾脏替代治疗支持的体外膜氧合患者中管路寿命比较:E-CRRT随机对照试验
该多中心随机对照试验于2021年5月至2025年3月纳入80例需CRRT支持的ECMO患者,随机分为集成组(40例)与分离组(40例),主要终点为CRRT管路寿命。结果显示两组管路寿命中位数无显著差异(72 h [IQR 45-96.5] vs 71 h [IQR 45-84],p=0.52),28天死亡率(32.5% vs 35%,p=0.81)及严重不良事件(包括空气栓塞)发生率亦无显著差异,跨膜压和CRRT机器报警频率相似。结论认为两种连接方式在滤器寿命和严重不良事件方面无显著差异。
要点
- 在需CRRT支持的ECMO患者中,集成组与分离组的CRRT管路寿命中位数无显著差异(72 h [IQR 45-96.5] vs 71 h [IQR 45-84],p=0.52)。
- 两组28天死亡率无显著差异(集成组32.5% vs 分离组35%,p=0.81)。
- 严重不良事件(包括空气栓塞)发生率在两组间无显著差异。
- 跨膜压和CRRT机器报警频率在两组间相似。
- 目前集成与分离两种技术均不被视为标准治疗。
适用人群与场景
- 需连续性肾脏替代治疗(CRRT)支持的体外膜氧合(ECMO)危重患者。
研究设计与关键结果
- 多中心随机对照试验,纳入80例需CRRT支持的ECMO患者,集成组40例,分离组40例。
- 主要终点CRRT管路寿命中位数:集成组72 h(IQR 45-96.5) vs 分离组71 h(IQR 45-84),p=0.52,无显著差异。
- 28天死亡率:集成组32.5% vs 分离组35%,p=0.81,无显著差异。
- 严重不良事件(包括空气栓塞)发生率无显著差异;跨膜压和CRRT机器报警频率两组相似。
证据类型、等级与局限
- 证据类型:多中心随机对照试验(E-CRRT Trial,注册号NCT05036616)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在需CRRT支持的ECMO危重患者中,集成与分离两种连接方式在滤器寿命和严重不良事件方面无显著差异,两者均不被视为标准治疗。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The estimated incidence of acute kidney injury requiring renal replacement therapy (RRT), mainly continuous RRT (CRRT), in patients necessitating extracorporeal membrane oxygenation (ECMO) is approximately 50%. Currently, two well-known techniques, integration and separation, are utilized for combining CRRT and ECMO circuits, neither of which is considered a standard treatment.
PURPOSE: This study aimed to compare circuit lifespan of CRRT between these two techniques during ECMO support.
METHODS: A multicentered randomized controlled trial was conducted from May 2021 to March 2025. ECMO patients who required CRRT support were enrolled. Primary outcome was CRRT circuit lifespan.
RESULTS: Eighty patients were recruited, with 40 allocated to the integration group and 40 to the separation group. Median circuit lifespan did not significantly differ between the groups (72 h [IQR 45-96.5] vs. 71 h [IQR 45-84]; p = 0.52). Twenty-eight-day mortality rates were also comparable (32.5% vs. 35%; p = 0.81). No significant differences were observed in the incidence of serious adverse events, including air embolism. Transmembrane pressure and CRRT machine alarm frequencies were similar between groups.
CONCLUSION: Among critically ill ECMO patients receiving CRRT, there is no significant difference in filter lifespan and serious adverse events between integrating the CRRT circuit into the ECMO circuit and using a separate circuit.
TRIAL REGISTRATION: NCT05036616.
参考来源
- Tangjitaree P, Thanapongsatorn P, Sinjira T, et al. The comparison of circuit lifespan between integration and separation approach in extracorporeal membrane oxygenation patients requiring continuous renal replacement therapy support: a randomized controlled trial (E-CRRT Trial). Intensive Care Med. 2026. PMID: 41642325. doi:10.1007/s00134-026-08302-y
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。